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Cystic fibrosis (CF) is a well-known inherited multisystem disorder characterised primarily by chronic
obstructive lung disease and maldigestion. The frequency
of the disease varies among ethnic groups, being the
highest in northern Europe where about 1 in 2500 newborns is affected. The CF gene itself is quite large; the
coding region is made up of 27 exons and the gene product is called cystic fibrosis transmembrane conductance
regulator (CFTR). A 3 base pair deletion in exon 10 of the
gene, which results in the loss of a single amino acid,
phenylalanine, is identified in approximately 70% of CF
patients and designated as ▲F508 (1,2,3). The frequency of this mutation varies among different populations,
being higher in northern Europe with respect to southern
Europe (4). The aim of this study was to set up a method
in our laboratory for the detection of the ▲F508 mutation and to obtain an estimate of the frequency of this
mutation in CF patients in the ‚ukurova region. The samples of blood were obtained from patients who were
diagnosed as having cystic fibrosis by the Paediatric
Metabolism Clinic according to their clinical symptoms
and sweat chloride test results. DNA was prepared from
leukocytes for the amplification reactions. Selected portions of DNA are amplified by a polymerase chain reaction. Heteroduplices are generated by heat denaturation
and reannealing of a mixture of wild type and mutant
DNA molecules. A heteroduplex between the normal and
mutant sequences is detected as extra bands of slower

mobility in a polyacrylamide gel system, providing a convenient test for identifying heterozygous individuals.
However, since the 3 base pair deletion is relatively small,
it is impossible to discriminate between a homozygous
patient and one without the deletion. To differentiate
between these two genotypes, DNA of a normal sequence
is added in equal amounts to each of the test samples, and
if a mutant sequence exists in the DNA mixture, as in the
homozygous cases, then heteroduplices form after the
amplification. In 8% (w/v) polyacrylamide gel, homoduplices and heteroduplices exhibit distinct electrophoretic
mobilities. The bands are visualised under UV light by
ethidium bromide staining (5,6). A total of 51 patients
(102 chromosomes) were included in our study. The paediatricians set the diagnostic criteria by the clinical assessment and a cut-off point of 60 meq/L for the sweat chloride test as the average of triplicate analysis. A total of 7
heterozygotes and only one homozygote for ▲F508
were detected and the frequency was calculated to be
8.8%. The homozygous patientsÕ DNA showed a single
band, just like the wild type, at the beginning, but the
polymerase chain reaction of the mixture of normal DNA
and the patient DNA sample in equal amounts revealed
the characteristic heteroduplices. The mutation was also
detected in the parents of the homozygous and they were
found to be the carriers of ▲F508 as expected, and the
diagnosis was confirmed (Figure). Genetic counselling
was given to this couple, and prenatal diagnosis is pro-
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The heteroduplices of the parents of the homozygous
patient. 1. Heterozygous Control; 2. Mother; 3. Father; 47 other patients (after the application of mixture of equal
amounts of normal and Patient DNA, still giving a single
band; excluding ▲F508 mutation; need to search for other
mutations); 8. Homozygous Control.

posed for further pregnancies. The results of the mutation analyses from 35 centres of Europe in 1990 were
published in a special issue of Human Genetics and the
discussions on the variety of mutations have started

worldwide. Across Europe and neighbouring areas of
Asia, there is a clear northwest to southeast gradient in
the relative frequency of ▲F508 (7). Cystic fibrosis is
known to be less common in the other groups, but significant numbers of affected individuals are found in
southern Europe, in the Ashkenazi Jewish population,
and in American blacks. Almost 90% of the cystic fibrosis mutations detected in the Danish population are
▲F508 (8). In contrast, while only 22% of the CF chromosomes in the Ashkenazi Jewish population in
Jerusalem carry ▲F508, the frequency for W1282X is
60% (9,10). In 1990, the only results about Turkish
population were detected by German scientists as 22%
from the Turkish minority living in West Germany (11).
Afterwards, Onay et al. from Istanbul and YÝlmaz et al.
from Ankara, published 15% and 28.4% frequencies of
the ▲F508 mutation in Turkish CF patients, respectively
(12,13). It was rather surprising to find out that our
result of 8.8% is even lower than those from Üstanbul
and Ankara. We found that only eight of the fifty-one CF
patients carried the DF508 mutation. Therefore, it would
be very interesting to search for the unknown mutations
and perhaps find a Turkish type of mutation just like the
W1282X mutation in Israel.
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